Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03207347 · ClinicalTrials.gov registry record · Phase 2
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
A Phase 2 study of Renal Cell Carcinoma and Cholangiocarcinoma, sponsored by University of Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
- 3
- Study locations
NCT03207347: Completed Phase 2 study of Renal Cell Carcinoma and Cholangiocarcinoma, sponsored by University of Florida.
NCT03207347 is a Phase 2 study of Renal Cell Carcinoma and Cholangiocarcinoma that has completed, run by University of Florida. The registered enrollment target is 37 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03207347, a Phase 2 study of Renal Cell Carcinoma and Cholangiocarcinoma, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
- 3
- Study locations
Study Summary
This open-label, non-randomized study will investigate the use of niraparib in patients with tumors known to have mutations in BAP1 and other select DNA damage response pathway genes.
Primary Outcome
Determine the objective response rate (ORR), which is defined as the percentage of subjects achieving a best overall response of partial or complete response (according to RECIST v1.1 criteria) from the start of the treatment until disease progression/recurrence or 30 days after the end of treatment, whichever occurs first. Per RECIST v1.1 criteria, a partial response is defined as a 30% or more decrease in the sum of the largest diameters of the target lesions. Per RECIST v1.1 criteria, a compl
Conditions Studied
Interventions
- DRUG Niraparib
Study Locations (3)
Florida
- University of Florida - Gainesville
- University of Miami - Miami
- Orlando Health UF Health Cancer Center - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2018-08-13 |
| Est. Completion | 2022-08-30 |
| Phase | Phase 2 |
What the finished NCT03207347 record still lists
NCT03207347 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (85% lower).
The record links to 4 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Niraparib is the first listed.
NCT03207347 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT03207347 about?
NCT03207347 is a clinical study titled "A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)". This open-label, non-randomized study will investigate the use of niraparib in patients with tumors known to have mutations in BAP1 and other select DNA damage response pathway genes.
What is the current status of trial NCT03207347?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2018-08-13. Estimated completion is 2022-08-30.
What conditions does trial NCT03207347 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma, Cholangiocarcinoma, Mesothelioma, Uveal Melanoma.
What interventions are being tested in trial NCT03207347?
The interventions under investigation include: Niraparib (DRUG).
Who is sponsoring clinical trial NCT03207347?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03207347 being conducted?
This trial has 3 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03207347's enrollment target sits among peer trials
37 88th of 121 higher than 34 of 121 other Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation
RECRUITING · Phase 2
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
-
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI